中华肝脏病杂志最新文献

{"title":"[Analysis of HCV genotype distribution characteristics in the Hotan region].","authors":"Maimaitijiang Wubuliaishan, H L Lyu, Aminai Aibi, J Z Bai, D Y Zhang, Nuerbiyi Maitikuwan, L Chen, W Y Zhang, J F Lu","doi":"10.3760/cma.j.cn501113-20241001-00525","DOIUrl":"10.3760/cma.j.cn501113-20241001-00525","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the distribution characteristics of hepatitis C virus (HCV) genotypes in the Hotan region, Xinjiang. <b>Methods:</b> The genotype and retrospective analysis of clinical data of patients with chronic HCV infection who visited the Hotan regional Infectious Disease Specialist Hospital from January 2021 to July 2024 were collected. The distribution characteristic of each genotype was analyzed. <b>Results:</b> A total of 1 366 cases with chronic HCV infection were collected. Seven hundred and ten were males, with an average age of (44.87±14.63) years. Genotype distribution:Patients with genotype 1b, 2a, 3a, 3b, and 6a accounted for 72.33% (988/1 366), 1.46% (20/1 366), 15.81% (216/1 366), 10.03% (137/1 366), and 0.37% (5/1 366), respectively. Genotype 1b patients were centered between 30-59 years old, with a higher detection rate in females than in males, while genotypes 3a and 3b were mainly between 30-49 years old, with a higher detection rate in males than in females.The patients in Pishan County, Moyu County, and Hotan County in Hotan region were mainly of genotype 1b, while the proportion of genotype 3 was relatively high in Hotan City, Luopu County, and Yutian County. <b>Conclusions:</b> The distribution of HCV genotypes in the Hotan region is diverse, with genotype 1b being the main one, and genotype 3 accounting for a high proportion. Therefore, it is recommended to actively conduct HCV genotype testing in key regions and populations to formulate optimized antiviral treatment plans and improve treatment efficacy.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"3-7"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study on the efficacy and safety profile of tenofovir alafenamide fumarate in the treatment of patients with decompensated hepatitis B cirrhosis].","authors":"F Guo, X Wu, J Dou, Z H Ning, X B Wang, Q Xu, F P Ji, Y H Yue, Z G Wang, S S Dang, H F Wang, Q Fu, S T Zeng, W Z Zuo, X Z Wang","doi":"10.3760/cma.j.cn501113-20240905-00479","DOIUrl":"10.3760/cma.j.cn501113-20240905-00479","url":null,"abstract":"<p><p><b>Objective:</b> To explore the efficacy and safety profile of tenofovir alafenamide fumarate (TAF) in the treatment of patients with decompensated hepatitis B cirrhosis. <b>Methods:</b> A two-way cohort study method was used to enroll patients with decompensated hepatitis B cirrhosis who visited four medical centers, including Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine, from April 2021 to April 2024 and were treated with TAF and followed up for 48 weeks. The primary efficacy indicator was hepatitis B virus (HBV) DNA seronegative conversion rate at 48-weeks, and the secondary efficacy indicator was alanine aminotransferase (ALT) return to normal rate at 48-weeks. Relevant safety indicators, adverse drug reactions (ADRs), and clinical adverse outcomes were collected. <b>Results:</b> A total of 74 cases were included. Of these, 52 were males with an average age of (53.14 ± 9.15) years. Twenty-five and thirty-three cases completed 24 and 48 weeks of follow-up, respectively. The HBV DNA negative conversion rate was 96.97% (32/33), which was higher than the baseline of 58.1% (43/74) following 48 weeks of TAF treatment. The ALT return to normal rate was 72.73% (24/33), which was higher than the baseline of 47.30% (35/74); however, the renal function and blood lipid levels did not change significantly compared with the baseline level after completing 48 weeks of treatment (P>0.05). During the follow-up period, one case developed hepatocellular carcinoma, and no other adverse clinical outcomes, such as liver transplantation or death, were reported. <b>Conclusion:</b> TAF has a good efficacy and safety profile in the treatment of patients with decompensated hepatitis B cirrhosis.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"14-20"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on hepatitis B combined with C and its treatment].","authors":"Q Lin, S W Guan, H Q Tu, X C Ye, M H Peng, K L Zhang, J Cai","doi":"10.3760/cma.j.cn501113-20241015-00540","DOIUrl":"10.3760/cma.j.cn501113-20241015-00540","url":null,"abstract":"<p><p>HBV/HCV dual infection is not uncommon, especially in highly endemic areas and among individuals at elevated risk of infection, because of the common transmission mode of hepatitis B virus (HBV) and hepatitis C virus (HCV) and may be underestimated due to the presence of occult HBV infection. HBV/HCV dual infection is associated with more rapid progression to advanced severe liver disease, severely increased fibrosis or cirrhosis, liver decompensation, and the development of hepatocellular carcinoma, thus requiring effective antiviral treatment. However, the intracellular interaction between HBV and HCV has not been fully elucidated at present. This paper summarizes the recent research on HBV/HCV dual infection and the current status of treatment and emphasizes the aspects that need further clarification in order to provide a basis for exploring treatment strategies for dual infection.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"68-72"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The distributions of serum HBsAg level in chronic hepatitis B patients based on the China Registry of Hepatitis B (CR-HepB)].","authors":"S Y Chen, S Shan, Y Y Kong, X Q Xu, H Wang, X N Wu, J L Zhou, B Q Wang, T T Meng, M Y Zhang, J D Jia, Y M Sun, H You","doi":"10.3760/cma.j.cn501113-20240723-00337","DOIUrl":"10.3760/cma.j.cn501113-20240723-00337","url":null,"abstract":"<p><p><b>Objective:</b> To determine the distributions of serum HBsAg level in treatment-naive or treatment-experienced chronic hepatitis B (CHB) patients. <b>Methods:</b> Based on the China Registry of Hepatitis B (CR-HepB), a nationwide hospital-based electronic platform, treatment-naive or treatment-experienced CHB patients who receive nucleos(t)ide analog (NA) therapy were enrolled in our study. We collected patients' clinical characteristics, including demographic, virological and biochemical data. The distributions of HBsAg levels in those two groups were summarized with counts and percentages. Continuous variables were expressed as median (interquartile range, IQR) or mean±SD. <b>Results:</b> A total of 13 505 treatment-naive CHB patients and 6 309 patients with previous NAs therapy were enrolled in the final analysis. The proportion of patients in those two groups with serum HBsAg<100 IU/ml, <500 IU/ml, <1 500 IU/ml or HBsAg level not lower than 1 500 IU/ml, 3 000 IU/ml or 8 000 IU/ml were 10.51% vs. 12.88%, 28.47% vs. 29.84%, 46.85% vs. 52.07%, 53.15% vs. 47.93%, 38.17% vs. 31.77%, 15.62% vs. 10.39%, respectively. HBsAg levels tended to decrease gradually with the duration of antiviral therapy: the percentage of patients with HBsAg levels below 100 IU/ml increased from 12.73% at less than 3 years of treatment to 26.92% at≥10 years of treatment, whereas the percentage of patients with HBsAg levels of 3 000 IU/ml or 8 000 IU/ml and above decreased from 34.66% to 23.08% and from 12.19% to 5.77%, respectively. <b>Conclusions:</b> Our investigation manifested the distribution of the serum HBsAg in treatment-naive CHB patients and patients who received previous NAs treatment. As the duration of antiviral therapy is prolonged, the HBsAg level tends to decrease gradually.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[B cells in chronic hepatitis: advances and mechanistic].","authors":"L L Tang, R N Xu, F S Wang","doi":"10.3760/cma.j.cn501113-20240809-00370","DOIUrl":"10.3760/cma.j.cn501113-20240809-00370","url":null,"abstract":"<p><p>The article reviews the role and functional diversity of B cells in chronic hepatitis B (CHB). B cells play a crucial role in humoral immunity, participating in the clearance of hepatitis B virus (HBV) through antibody production, antigen presentation, and immune regulation. In HBV infection, B cells exhibit antigenic heterogeneity, with immune responses to different HBV antigens varying. Recent findings reveal that in CHB patients, hepatitis B surface antibody-specific B cells are abnormally differentiated, while hepatitis B core antibody-specific B cells maintain relatively intact functions. Moreover, the deficiency in non-antibody-producing functions of B cells may lead to persistent HBV infection. The article provides important insights into the role of B cells in HBV infection and offers a scientific basis for the development of new therapeutic strategies.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Interventional studies on acute-on-chronic liver failure: challenges and opportunities].","authors":"P F Yu, M M Xu, Y Chen","doi":"10.3760/cma.j.cn501113-20240902-00465","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240902-00465","url":null,"abstract":"<p><p>Acute-on-chronic liver failure (ACLF) is a kind of complex syndrome characterized by acute deterioration of liver function on the basis of chronic liver disease, accompanied by organ failure and a high mortality rate. The International Society for Hepatology has proposed different definitions, diagnostic criteria, and treatment guidelines, which have led to differences in the clinical management of ACLF and underestimated the burden of the disease. Currently, there is no specific treatment for ACLF, and the overall prognosis is still not ideal. This article profoundly explores the problems existing in the interventional studies of ACLF and provides a new perspective for in-depth research on the pathogenesis and progression, the development of new intervention measures, the promotion of personalized treatment, and the formulation of more accurate diagnostic criteria and risk prediction models.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 12","pages":"1067-1072"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical progress in stem cell therapy for end-stage liver disease].","authors":"Y F Pan, Y B Xie, L Shi, M Shi, F S Wang","doi":"10.3760/cma.j.cn501113-20241018-00548","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20241018-00548","url":null,"abstract":"<p><p>End-stage liver disease includes liver failure and decompensated cirrhosis resulting from various etiologies and often leads to patient mortality due to complications and clinical symptoms such as severe jaundice, ascites, hepatic encephalopathy, coagulopathy, and hepatorenal syndrome. Liver transplantation is currently regarded as the most effective treatment, but its clinical application is limited by the shortage of donors, elevated expenses, and post-transplant rejection. Stem cells are a group of cells with multidirectional differentiation potential and self-renewal ability, which can improve the clinical indicator outcomes through mechanisms such as immunoregulation and promotion of tissue repair in patients with end-stage liver disease. Clinical trials of stem cell therapy have achieved a series of results for end-stage liver disease, proving the safety and effectiveness of stem cell therapy. This article reviews the clinical studies that have been registered and published at home and abroad and provides a reference for the clinical plan on stem cell therapy for end-stage liver disease.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 12","pages":"1060-1066"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Meta-analysis of the efficacy of the Fuzheng Huayu formula in the treatment of hepatitis B-associated liver fibrosis or cirrhosis].","authors":"Y Fan, K Y Hao, P Li, Z X Li, C H Liu, Y C Yu","doi":"10.3760/cma.j.cn501113-20240612-00293","DOIUrl":"10.3760/cma.j.cn501113-20240612-00293","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To systematically evaluate the efficacy of Fuzheng Huayu (FZHY) tablets/capsules on hepatitis B-associated liver fibrosis or cirrhosis based on randomized controlled trials (RCTs) in order to provide more accurate evidence-based medicine for clinical rational drug use. &lt;b&gt;Methods:&lt;/b&gt; Randomized controlled clinical trial research reports related to the treatment of hepatitis B-associated liver fibrosis or cirrhosis with FZHY published in SCI and statistical source core journals were retrieved from databases such as PubMed, Cochrane Library, and China National Knowledge Infrastructure (CNKI). RevMan 5.3 and Stata18.0 software were used to conduct a meta-analysis of the improvement rate of liver tissue inflammatory activity (HAI) and Ishak stage of liver fibrosis, the decrease value of liver stiffness measurement (LSM), hyaluronic acid (HA), laminin (LN), type Ⅲ procollagen (PC-Ⅲ), type Ⅳ collagen (IV-C), total bilirubin (TBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and albumin (Alb). The Q test was used for the heterogeneity test, with a random-effect model selected for large heterogeneity and a fixed-effect model for less heterogeneity. &lt;b&gt;Results:&lt;/b&gt; A total of 852 articles were retrieved. Duplicate articles, non-RCT articles, non-SCI/statistical source/core journal articles, and other articles that did not meet the inclusion criteria were sequentially excluded. Finally, a total of 2 746 cases (1 382 cases in the FZHY group and 1 364 cases in the control group) were included from 25 studies. The results of statistical analysis showed that the improvement rates of HAI grade of liver inflammation were 75.56% (68/90) and 42.22% (38/90, &lt;i&gt;P&lt;/i&gt;&lt;0.001) in the FZHY group and the control group at 24-48 weeks of treatment, while the improvement rates of Ishak stage of liver fibrosis were 67.90% (110/162) and 40.91% (63/154, &lt;i&gt;P&lt;/i&gt;=0.005), respectively. Compared with the control group (95%&lt;i&gt;CI&lt;/i&gt; -5.10-1.77, &lt;i&gt;P&lt;/i&gt;&lt;0.001) the mean △LSM of the FZHY group decreased by 3.43 kPa (&lt;i&gt;P&lt;/i&gt;&lt;0.001)and 0.30 kPa (&lt;i&gt;P&lt;/i&gt;=0.93) at 48 and 72 weeks of treatment. The standardized mean differences (SMDs) of △HA, △LN, △PC-Ⅲ and △Ⅳ-C were -1.12, -1.00, -0.89 and -1.10 (&lt;i&gt;P&lt;/i&gt;&lt;0.001) after 24 weeks of treatment between the FZHY group and the control group. The SMDs of △HA, △IV-C, △LN and △PC-Ⅲ were -1.13 (&lt;i&gt;P&lt;/i&gt;=0.01), -1.51 (&lt;i&gt;P&lt;/i&gt;&lt;0.001), -0.53 (&lt;i&gt;P&lt;/i&gt;=0.14) and -0.42 (&lt;i&gt;P&lt;/i&gt;=0.19) after 48 weeks of treatment between the two groups. The △TBil, △ALT, △AST, and △ALB was -12.99 μmol/L (&lt;i&gt;P&lt;/i&gt;=0.007), -36.91 U/L (&lt;i&gt;P&lt;/i&gt;&lt;0.001), -22.05 U/L (&lt;i&gt;P&lt;/i&gt;=0.12), and 6.09 g/L (&lt;i&gt;P&lt;/i&gt;=0.05) after 24 weeks of treatment between the two groups. The observation on indicators such as aspartate aminotransferase and platelet ratio index, fibrosis-4 index, and hepatocellular carcinoma incidence in current RCT studies remained deficient. &lt;b&gt;Conclusion:&lt;/b&gt; FZHY can significantly improve the degree of histologic liv","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 12","pages":"1141-1152"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Management standards and quality control index for the clinical application of transarterial chemoembolization in the treatment of liver cancer (2024 edition)].","authors":"","doi":"10.3760/cma.j.cn501113-20240902-00463","DOIUrl":"10.3760/cma.j.cn501113-20240902-00463","url":null,"abstract":"<p><p>Transarterial chemoembolization (TACE) is currently one of the commonly used treatment methods for liver malignancies. The key to ensuring its efficacy is high-quality TACE performance and management.Therefore, to further promote the quality control indicators line for TACE clinical application in the treatment of liver cancer, the National Center for Healthcare Quality Management in Comprehensive Interventional Radiology combined evidence-based medicine, expert consensus, and conditions in China to draft and formulate the \"Management standards and quality control index for the clinical application of transarterial chemoembolization in the treatment of liver cancer (2024 edition)\" so as to affirm the standardized, precise, and individualized application in clinical practice and improve the overall efficacy in patients with liver malignancies.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1098-1104"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical application and technical operation specification of dual plasma molecular adsorption system].","authors":"","doi":"10.3760/cma.j.cn501113-20240920-00500","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240920-00500","url":null,"abstract":"<p><p>The standard clinical application and operational specifications of the double plasma molecular adsorption system are summarized into eleven parts, including the treatment principles, indications and timing selection, treatment plan formulation principles, establishment and maintenance of vascular access, anti-coagulation strategy selection, instrument alarms and handling, and the efficacy evaluation indicators in the treatment of severe liver disease.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 12","pages":"1073-1085"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}